1,134
Participants
Start Date
January 31, 2007
Primary Completion Date
November 30, 2007
Study Completion Date
November 30, 2007
Valsartan/amlodipine 80/5 mg
1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily
Valsartan 80 mg
1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
Valsartan 160 mg
1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
Beijing ChaoYang Hospital, Affiliate of Capital University of Medical Sciences, Beijing
Beijing General Hospital of Beijing Military Region, Beijing
Beijing Hospital, Beijing
The First Affiliated Hospital of China Medical University, Shenyang
The people's Hospital of Liaoning Province, Shenyang
Second Military Medical University Affiliated Changzheng Hospital, Shanghai
Department of cardiology, Ruijin hospital;, Shanghai
Department of cardiology, Ruijin hospital, Shanghai
Fudan University affiliated zhongshan hospital, Shanghai
Second Military Medical University Affiliated Changhai Hospital, Shanghai
Southeast University Affiliated Zhong Da Hospital, Nanjing
The First Affiliated Hospital of Nanjing Medical University, Nanjing
The Second Affiliated Hospital of Soochow University, Suzhou
The First Affiliated Hospital of Soochow University, Suzhou
The First People's Hospital of Hangzhou, Hangzhou
The Second Affiliated Hospital of Medical College of Zhejiang University, Hangzhou
The First Affiliated Hospital of Medical College of Zhejiang University, Hangzhou
Second Hospital of Hebei University of Medical Sciences, Shijiazhuang
The People's Hospital of Hebei Provincial, Shijiazhuang
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY